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Interferon inductionse, in particular the production of type 1 interferons, is an essential part of the
mammalian host response to viral infection. We have previously shown that rinderpest virus, a morbillivirus
closely related to the human pathogen measles virus, blocks the actions of type 1 and type 2 interferons. We
show here that this virus can also block the induction of type 1 interferon. The viral non-structural C protein
appears to be the active agent, since expressing this protein in cells makes them resistant to activation of the
interferon-β promoter while recombinant virus that does not express the C protein activates this promoter
much more than virus expressing the C protein. In addition, differences in activation of the interferon-β
promoter by different strains of rinderpest virus are reﬂected in differing abilities of their respective C
proteins to block activation of the promoter by dsRNA. The C protein blocks the activation of this promoter
induced by either cytoplasmic dsRNA or by Newcastle disease virus (NDV) infection, as well as activation
induced by overexpression of several elements of the signalling pathway, including mda-5, RIG-I and IRF-3.
The RPV C protein also blocks transcription from promoters responsive individually to the three transcription
factors that make up the interferon-β promoter enhanceosome, although it does not appear to block the
activation of IRF-3.
© 2008 Elsevier Inc. All rights reserved.IntroductionHost defence against virus attack depends on the initial innate
immune response, in particular the induction of type 1 interferons
(IFNs) (IFN-α, β, λ and ω) in response to activation of various
pathogen-speciﬁc molecular patterns detected by pattern recognition
receptors (PRRs) (reviewed in Janeway and Medzhitov, 2002). These
PRRs can be extracytoplasmic (primarily the Toll-like receptors) or
cytoplasmic; the main types of cytoplasmic detectors of viruses so far
identiﬁed are dsRNA-activated enzymes such as protein kinase R
(PKR) and two caspase recruitment domain (CARD)-containing
proteins, retinoic acid-inducible gene 1 (RIG-I) and melanoma
differentiation-associated gene 5 (mda-5). Activation of these
receptors leads, via a complex network of signalling pathways, to
the induction of IFN synthesis, which in turn leads to the development
of a virus-resistant state in the surrounding cells, as well as the
activation and modulation of the adaptive immune system. Many
viruses have evolved mechanisms to avoid or block these host defence
systems. One tactic adopted by viruses is to block the induction of
interferon in the infected cell, while other viruses have evolved ways
to block the action of IFNs, usually by blocking the signalling pathwayron).
t, Sir James Black Centre, Dow
ndee DD1 5EH, UK.
l rights reserved.that leads to the induction of expression of the various proteins
involved in the virus-resistant state; many viruses have evolved both
strategies.
In the family Paramyxoviridae, the phosphoprotein (P) genes
encode one or more so-called non-structural proteins in addition to
the P protein proper; these proteins are expressed either through
utilisation of overlapping open reading frames (ORFs) (giving rise to
the proteins called C) (Bellini et al., 1985) or through a process known
as RNA editing (Cattaneo et al., 1989) which gives rise to the V and W
proteins. The non-structural proteins of several paramyxoviruses have
been implicated either in blocking IFN action or blocking its induction,
or sometimes both (reviewed in Goodbourn and Didcock, 2000; Gotoh
et al., 2002; Horvath, 2004). The genus Morbillivirus within the sub-
family Paramyxoviridae contains several important pathogens. In
addition to the human pathogen measles virus (MV), the group
contains the cattle pathogen Rinderpest virus (RPV), Canine and Phocid
distemper viruses, and Peste des petits ruminants virus, which causes
disease in sheep and goats. RPV has for centuries been the most feared
and lethal viral disease of cattle. Although now almost eradicated in
thewild (FAO, 2003), the virus remains an important subject for study,
not least because of the unsolved questions of what limits its ability to
cause disease to cattle, despite the close similarity to MV, and the use
of the same receptor by all morbilliviruses (Baron, 2005; Tatsuo et al.,
2001). The mechanism(s) by which morbilliviruses block IFN action or
induction are not yet clear. We have recently shown that RPV has
several distinct mechanisms for blocking IFN signalling (Nanda and
135E.L. Boxer et al. / Virology 385 (2009) 134–142Baron, 2006), the P and V proteins binding STAT1, leading to a block of
STAT1 phosphorylation and blocking IFN signalling, while the V
protein also efﬁciently blocks the phosphorylation of STAT2 by an as
yet unknown mechanism. The ability of morbilliviruses to block the
induction of IFN directly has not been shown, although previous work
has shown that MV infection in vivo leads to loss of innate immune
response (Naniche et al., 2000; Slifka et al., 2003). The MV V protein
has been shown to bind to mda-5 (Childs et al., 2007), suggesting that
it may also act to inhibit IFN induction, at least through this pathway.
On the other hand, a mutant MV that expresses V but does not express
the C protein induces more IFN than its parent virus (Nakatsu et al.,
2006; Shaffer et al., 2003), suggesting that the Cprotein is also involved
in blocking IFN induction. In this paper we show that the C protein but
not theVprotein of RPV inhibits the induction of IFN in infected cells. In
this respect, morbilliviruses seem to differ from the rubulaviruses (e.g.
parainﬂuenza virus 5 (PIV5)), which do not express a C protein and
where the V protein blocks both the induction and action of type 1 IFNs
(Poole et al., 2002), and the respiroviruses (e.g. Sendai virus (SeV),
where the C protein blocks IFN action (Komatsu et al., 2002) and both C
and V proteins (Komatsu et al., 2004) block induction.
Results
Initial studies in our lab (not shown) as well as previously
published data (Hussain et al., 1982) had suggested that some strains
of RPV induced more IFN than others when infecting bovine kidney
cells. Interpretation of these results was complicated by the fact that
IFN induced directly by the virus in infected cells would induce IFNFig. 1. RPV can suppress induction of IFN. (a–c) Vero-SLAM cells in 12-well plates were transf
cells were infected with equal amounts (based on 50% tissue culture infectious dose (TCID50
further 18 h, cells were lysed for luciferase and beta-galactosidase assays. (b) Six hours post-
left uninfected. 18 h post-infection, the cells were transfected with dsRNA or mock transfecte
Results from separate experiments were combined by setting the RLUs induced by dsRNA in
in 3–5 separate experiments. Error bars show standard deviations of the normalised data. (d
18 h post infection into SDS-PAGE sample buffer. Samples were analysed by Western blot usynthesis in neighbouring uninfected cells, amplifying to an unknown
extent the apparent activity of the virus. In order to obtain a direct
measure of the extent to which different strains of RPV induced IFN
synthesis we used Vero cells, which lack a functional IFN-β gene
(Emeny and Morgan, 1979; Mosca and Pitha, 1986). The Vero cell line
used had been further modiﬁed to express the wild type morbillivirus
receptor CD150/SLAM (Ono et al., 2001), eliminating any major
variation in entry ability between different strains of virus.
Cells were transfected with a plasmid containing the promoter for
human IFN-β driving the expression of the reporter gene luciferase
(pIFΔ(−116)lucter) and then infected with equal amounts of the
virulent RPV strains Saudi/81 (RPV-Sa) and Kabete ‘O’ (RPV-KO), or the
vaccine strain RPV-RBOK. Whereas the vaccine strain induced strong
luciferase synthesis (70% of the level induced by transfection of the
cells with dsRNA), RPV-Sa induced hardly any (Fig. 1a). Interestingly,
the RPV-KO strain, which is equally as virulent as the RPV-Sa strain,
showed an intermediate level of activation of the IFN-β promoter,
suggesting that induction of IFN does not preclude a virus from being
virulent. Since all the strains used appear, from immunoﬂuorescence
studies, to enter Vero-SLAMs efﬁciently, and all grow equally well in
Vero-SLAM cells (similar amounts of viral protein found in cells
infected with each strain of RPV (Fig. 1d), and all grow to about 106
TCID50 units/ml), we deduced that RPV-Sa was either better than the
others at avoiding triggering the IFN-induction pathway (perhaps
because it generated less dsRNA during replication) or was better at
blocking the pathway in some way. Infecting cells at high multiplicity
of infection (moi), so that almost all of the cells would be infected, and
then transfecting the infected cells with dsRNA, showed that RPV wasected with 1 μg of each of pIFΔ(−116)lucter and pJatLac. (a), (c) 6 h post-transfection the
)) of the indicated virus or transfected with dsRNA (poly(I:C)) or left untreated. After a
transfection, cells were infected with RPV-Sa at a multiplicity of infection (moi) of 2.5 or
d. After a further 24 h, cells were lysed for luciferase and beta-galactosidase assays. (a–c)
uninfected cells to 100%; all experiments were performed in duplicate or triplicate wells
) Vero-SLAM cells were infected with the indicated virus as in (a) and (c) and harvested
sing mouse anti-RPV P protein.
136 E.L. Boxer et al. / Virology 385 (2009) 134–142blocking the pathway, since hardly any luciferase was induced by
dsRNA in RPV-Sa-infected cells (Fig. 1b). Note that in cells infected
with similarly high levels of RPV-RBOK, luciferase induction was
already almost as high as the maximum achievable by dsRNA
transfection in mock infected cells (not shown), so it is not possible
to determine to what extent this strain of the virus is able to block
activation of the IFN-β promoter.
In order to studywhich viral proteinwas responsible for the block of
IFN induction,wemade use of a pre-existing set of gene swaps between
RPV-RBOK (high IFN inducer) and the virulent parent, RPV-KO
(moderate IFN inducer) (Baron et al., 2005). Swapping the P gene
between these two strains gave us chimaeric viruses RPV-KO(RBOK P)
and RPV-RBOK(KO P) (KO-RP and RBOK-KP). It also swapped the IFN-β
promoter activation phenotype, so that KO-RP became a high inducer
while RBOK-KP became a moderate inducer (Fig. 1c). These data
suggested that the control of IFN induction lies with the viral P, V or C
proteins.
To determine which of these proteins was responsible, we
transfected Vero cells with the pIFΔ(−116)lucter reporter construct
along with plasmids from which the RPV-Sa P, V or C proteins are
expressed; the P and V expression constructs weremutated to preventFig. 2. The RPV C protein suppresses interferon induction. (a) Vero-SLAM cells were transfecte
of the indicated viral protein (or empty vector for “none”). 24 h post-transfection the cells we
lysed and luciferase and beta-galactosidase assays performed as in “Materials and methods”
plasmid driving the expression of the indicated viral protein (or empty vector for “none”). 30
further 18 h the cells were lysed and luciferase and beta-galactosidase assays performed as i
setting the RLUs induced by dsRNA or NDV in cells transfected with empty vector to 100% (
post-transfection cells were infected with equal amounts (moi≈0.3) of the indicated viruses o
cells were lysed and luciferase and beta-galactosidase activities measured; results from sepa
bars show standard deviations of normalised data. (e) Vero-SLAM cells were transfected wit
same way as for (a). Samples were harvested 48 h post-transfection into SDS-PAGE sample bu
the V5 epitope tag.expression of the C open reading frame (Nanda and Baron, 2006). A
plasmid encoding the V protein of PIV5 was used as a positive control
for suppression of IFN induction. The cells were subsequently
transfected with dsRNA to induce luciferase synthesis. As can be
seen in Fig. 2a, expression of the V protein of PIV5 strongly (but not
completely) suppressed the activation of the IFN-β promoter, as has
previously been reported (He et al., 2002). The RPV P protein had no
effect on the induction of luciferase. To our surprise, given the
reported activities of other paramyxovirus V proteins, the RPV V
protein also had no effect, whereas the RPV C protein was as effective
as the PIV5 V protein. We also compared the ability of the C proteins
from RPV-Sa and RPV-RBOK to suppress activation of the IFN-β
promoter; as predicted from the relative activation of this promoter by
infectionwith these two viruses, the RBOK C proteinwas less effective
than that of RPV-Sa at suppressing dsRNA-stimulated activation of the
IFN-β promoter (Fig. 2a), although still showing partial suppression.
All these proteins were expressed at similar levels, as judged by
Western blot using the V5 epitope common to all constructs (Fig. 2e),
with the exception of the C protein of RPV-RBOK. Interestingly, this
protein was always found at lower levels than the RPV-Sa C protein,
whether we used different preparations of this plasmid or anotherdwith 0.5 μg each pIFΔ(−116)lucter, pJatLac and 1 μg of a plasmid driving the expression
re transfectedwith dsRNA (poly(I:C)) or left untreated. After a further 24 h the cells were
. (b) A549 cells were transfected with 0.5 μg each pIFΔ(−116)lucter, pJatLac and 1 μg of a
h post-transfection the cells were infectedwith NDV (moi≈1.5) or left uninfected. After a
n “Materials and methods”. (a,b) Results from separate experiments were combined by
c,d) Vero-SLAM cells were transfected with 1 μg each pIFΔ(−116)lucter and pJatLac. 6 h
r transfected with dsRNA or left untreated (“none”). 18 h post-infection/transfection the
rate experiments were combined by setting the RLUs induced by dsRNA to 100%. Error
h plasmids driving the expression of the indicated viral protein, or empty vector, in the
ffer and the expressed proteins detected byWestern blot using monoclonal antibody to
Fig. 3. The RPV C protein suppresses transcription from promoters containing any of the
PRDs of the IFN-β promoter. Vero cells were transfected with 0.5 μg pJatLac, 1 μg of a
plasmid encoding the indicated viral protein (or empty vector for “none”) and 0.5 μg of
(a) p55C1B-luc, (b) p55A2-luc, (c) pAP1-luc. 24 h post-transfection the cells were
transfectedwith dsRNA (poly(I:C)) or left untreated. 24 h post transfection the cells were
lysed and luciferase and beta-galactosidase assays performed as in “Materials and
methods”. Results from separate experiments were combined by setting the RLUs
induced in cells transfectedwith empty vector to 100%; all experiments were performed
at least three times. Error bars show standard deviations of the normalised data.
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as two bands in the case of RPV-Sa C protein. It may be that the relative
inefﬁciency of the RBOK C protein in blocking activation of the IFN-β
promoter is due to a relative instability of the protein; further studies
on the stability of the C proteins from different RPV isolates will be
required to clarify this point.
Although both RIG-I and mda-5 were originally thought to be
sensors for dsRNA (a common by-product of viral infection), it has
recently been shown that RIG-I is a sensor for RNA with the 5′
triphosphate typical of many RNA virus genomes and mRNAs, while
mda-5 appears to be required for responding to viruses which do not
have 5′ triphosphate, but do produce intracellular dsRNA (Hornung
et al., 2006; Kato et al., 2006; Pichlmair et al., 2006); speciﬁcally,mda-5
is the sensor for the poly(I:C) used in these studies as dsRNA (Gitlin
et al., 2006; Kato et al., 2006). Since the RPV C protein blocked
activation of the IFN-β promoter by intracellular (transfected) dsRNA
(which lacks a 5′ triphosphate), it appears to block themda-5 pathway.
In order to testwhether the C protein can also block the RIG-I pathway,
we transfected cells with the pIFΔ(−116)lucter construct along with
the PIV5 V, RPV C or RPV V constructs, and then infected them with
Newcastle disease virus (NDV), an avian paramyxovirus which can
infect mammalian cells but not replicate effectively because of its
inability to block induction of IFN in mammalian cells (Park et al.,
2003). For these studies, we used A549 cells rather than Vero cells
since the latter, unable to express type 1 IFNs, are rapidly killed byNDV.
We found that both the PIV5 V and RPV C protein blocked activation of
the IFN-β promoter by NDV while, as with dsRNA, the RPV V protein
waswithout effect (Fig. 2b). Interferon induction byNDV requires RIG-I
(Kato et al., 2005), and we conﬁrmed this was so for our NDV
preparation by testing it on transfected Huh-7.5 cells. These cells
have an inactivating mutation in their RIG-I protein, but a normal
mda-5 protein, and so respond normally to transfected poly(I:C)
(Sumpter et al., 2005). As expected, transfected poly(I:C) induced
expression of luciferase from the pIFΔ(−116)lucter plasmid in Huh7.5
cells, but infection with NDV did not (data not shown), conﬁrming
that the NDV was acting through RIG-I.
We also tested the activity of the RPV V and C proteins in the
context of virus infection. For this we used previously made V and C
knock-out versions of the RBOK strain of RPV (Baron and Barrett,
2000). Although RPV-RBOK is quite effective at inducing IFN, the
partial activity of the RPV-RBOK C protein in suppressing activation of
the IFN promoter suggested that preventing C expression should
increase IFN induction by this virus. As shown in Fig. 2c, infection of
Vero-SLAM cells previously transfected with the pIFΔ(−116)lucter
reporter construct with equal doses of RPV-RBOK or the V− or C−
mutants conﬁrmed this prediction, since RPV-RBOK and RBOK-V−
induced the same amount of luciferase, while RBOK-C− induced nearly
60% more, inducing almost as much luciferase as transfecting the cells
with dsRNA.
These data indicated that the C protein is primarily responsible for
suppressing activation of the IFN-β promoter, and that the C protein of
the RPV-Sa strain was particularly good at this, so we tested this
further by making recombinant RBOK viruses containing the P gene
from RPV-Sa with or without C protein expression. Replacing its
normal P gene with that of RPV-Sa made RBOK a low inducer of IFN,
and this required a C protein, since RPV-RBOK-SaPCstop was a high
inducer of IFN (Fig. 2d).
The IFN-β promoter contains four positive regulatory domains
(PRDs), which are binding sites for three different transcription factors,
interferon regulatory factor 3 (IRF-3) (PRDs I and III), nuclear factor-κB
(NF-κB) (PRD II) and activating protein 1 (AP-1) (PRD IV). Maximal
activation of the promoter requires the assembly of a so-called
enhanceosome on the PRDs (reviewed in Maniatis et al., 1998).
Intracellular dsRNA or viral RNA leads to the activation of all three
transcription factors by a complex set of pathways, and we
investigated whether the action of the RPV C protein was such as toblock all three transcription factors. The PRDs can, by themselves, act
as activation domains. We used constructs in which luciferase
expression was regulated by IRF-3 (p55C1B-luc), NF-kB (p55A2-luc)
or AP-1 (pAP-1-luc) to see which pathways were being blocked by the
C protein. As shown in Fig. 3, both PIV5 V and RPV C effectively blocked
activation of all three transcription factors by transfected dsRNA,
though with some small but consistent differences between the two
viral proteins. Whereas the PIV5 V protein was consistently better
than RPV C at blocking induction through activation of IRF-3 (Fig. 3a),
RPV C was consistently better than PIV5 V at blocking induction
through activation of NF-kB (Fig. 3b). Both proteins were equally
effective at blocking induction mediated by AP-1 (Fig. 3c).
These data suggest that the two viral proteins are acting by
different mechanisms. The point of action of the RPV C protein could
be early, e.g. preventing the activation of mitochondrial anti-viral
signalling protein (MAVS) (Seth et al., 2005) by RIG-I or mda-5; since
Fig. 4. RPV C acts at a late stage in the IRF-3 activation pathway. Vero cells were transfected with 0.5 μg each pIFΔ(−116)lucter, pJatLac and 1 μg of a plasmid driving the expression of
the indicated viral protein (or empty vector for “none”) along with (a) 500 ng of pcDNA or expression constructs encoding mda-5 or RIG-I; (b–d) 200 ng of pcDNA or expression
constructs encoding (b) MAVS, (c) TBK-1 or IKK-ɛ, or (d) IRF-3. 24 h post transfection the cells were lysed and luciferase and beta-galactosidase assays performed as in “Materials and
methods”. Results from separate experiments were combined by setting the RLUs induced in cells transfected with empty vector to 100%; all experiments were performed at least
three times. Error bars show standard deviations of the normalised data.
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tumour necrosis factor (TNF) receptor associated factor 3 (TRAF3)
(leading to activation of IRF-3) and the inhibitor-κB kinase (IKK)
complex (leading to activation of NF-kB and possibly AP-1), blocking
at this stage would block activation of all three transcription factors.
Alternatively, the point of action could be late, e.g. in the nucleus,
preventing the formation of an active transcription complex. We
therefore investigated the ability of the RPV C protein to block
activation of transcription from the IFN-β promoter induced by
overexpression of a variety of components of the pathway leading to
IRF-3 activation. Overexpression of mda-5, RIG-I or MAVS in Vero cells
led to activation of transcription from the IFN-β promoter-luciferase
reporter plasmid, as previously reported (Childs et al., 2007), and this
activity is suppressed by co-expression of the RPV C protein (Figs. 4a,
b). These data showed that the point of action of C is downstream of
the initial signal from the cytoplasmic PRRs to MAVS. Overexpression
of IKK-ɛ or TANK binding kinase 1(TBK1), both involved in activation
of IRF-3 (Sharma et al., 2003), or overexpression of IRF-3 itself, led to
activation of transcription from the reporter plasmid, and again RPV-C
blocked these effects (Fig. 4c, d). Taken together with the observations
in Fig. 3, it is probable that the RPV C protein is acting to block
processes downstream of the activation of IRF-3, possibly somewhere
in the nucleus.
We therefore looked at the activation and nuclear translocation of
IRF-3 in infected and transfected cells. A549 cells were used because
they show clear endogenous IRF-3, which accumulates in the nucleus
when activated either by transfection with dsRNA or infection of the
cells with NDV (Hiscott, 2007 and references therein). As these cells
(unlike Veros) produce type 1 IFNs, we blocked any side effects of RPV-
infection induced IFN by blocking the cell type 1 IFN receptor with a
receptor-neutralising antibody (see ‘Materials andmethods’). Infection
of the cells with RBOK-SaP (Fig. 5) or RPV-Sa (not shown) led to thetranslocation of IRF-3 to the nucleus, showing that RPV did not itself
block IRF-3 activation. Similar results were found when cells were
transfectedwith plasmids expressing RPV C or RPVV and infectedwith
NDV as an activator of IRF-3. Expression of either viral protein failed to
block activation of IRF-3 (Fig. 5) (note that, for the transfected cells,
ﬁelds were deliberately selected containing cells with very high and
low levels of viral protein expression). These data suggest that the virus
is able to block induction of interferon at a point downstream of
activation of IRF-3, since C protein expression blocks the activation of
the IFN-β promoter (Fig. 2) but does not block the activation of IRF-3
(Fig. 5). The observation that the RPV C protein is largely nuclear-
located is in agreement with the idea that it may be having a direct
effect on the formation of the transcription complex on the IFN-β
promoter.
Discussion
Examination of the sequences of the P genes of rhabdoviruses and
paramyxoviruses has suggested that the varied methods of generation
of non-structural proteins in the sub-family Paramyxoviridae have
arisen as the result of several independent evolutionary events (Jordan
et al., 2000). An evolutionary event that introduced RNA editing and
the production of V proteins seems to have predated the generation of
the several genera in the paramyxoviridae, since it is shared by almost
all members of that sub family; the V protein zinc-binding motif is
highly conserved and is required for many of the special functions of V
proteins (Childs et al., 2007; He et al., 2002; Kubota et al., 2001; Nishio
et al., 2005; Ulane et al., 2005). Later separate events seem to have
given rise to the generation of C proteins in most of the individual
genera, though it is notable that there appears to be no conserved
sequences between the C proteins of the respiroviruses, the
morbilliviruses and the avian paramyxoviruses.
Fig. 5. RPV does not block the activation of IRF-3. (a–d) A549 cells were mock infected
or infected with rRPV-SaP at a moi≈0.1 in the presence of interferon receptor-
blocking monoclonal antibody. Cells were ﬁxed and processed for ﬂuorescence
labeling 18 h post-infection. (e–j) A549 cells were transfected with plasmid encoding
RPV-Sa C (g,h) or V (i,j) proteins or left untransfected (e,f). 24 h post-transfection the
cells were infected with NDV (moi≈1.5). After a further 6 h, cells were ﬁxed and
processed for immunoﬂuorescence labeling. Cells were stained with rabbit anti-IRF-3
(a,c,e,g,i,) and either mouse anti-RPV P protein (b,d) or mouse anti-V5 tag to stain the
V or C proteins (f,h,j).
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found to be involved in blockade of the IFN signalling pathway. It is
possible that some functionality against IFN action was present in the
P protein of an early ancestor of all the Mononegavirales, as the
rhabdovirus P protein has also been found to be involved in blocking
IFN action (Vidy et al., 2005) and induction (Brzozka et al., 2005).
Despite the conservation of sequences between the V proteins of
different viruses, different paramyxoviruses have developed different
ways of using these proteins to block IFN signalling, in some cases
leading to degradation of STAT1 (Didcock et al., 1999) or STAT2(Andrejeva et al., 2002), in others binding to STAT1 or STAT2 (Gotoh
et al., 2003; Nanda and Baron, 2006; Rodriguez et al., 2002) or
preventing the activation of IFN-receptor-associated kinases (Yokota
et al., 2003). In the respiroviruses, the V protein does not seem to have
a role in blocking IFN action, that function having passed in some way
to the C protein(s) (Garcin et al., 2002; Gotoh et al., 2003).
More recent data has associated the paramyxovirus V proteins with
blockade of the induction of type 1 IFNs, speciﬁcally binding to the PRR
mda-5 (Andrejeva et al., 2004; Childs et al., 2007) and blocking its
activation by dsRNA. As commented by those authors, it remains to be
determined why paramyxoviruses have evolved a mechanism to
blockade speciﬁcally the dsRNA sensormda-5when normal replication
of negative strand RNA viruses generates undetectable amounts of
intracellular dsRNA (Weber et al., 2006) while activating the RIG-I
pathway due to the presence of a 5′ triphosphate on the viral genome
(Hornung et al., 2006; Pichlmair et al., 2006; Plumet et al., 2007). There
is evidence from different groups for a central role for either mda-5
(Berghall et al., 2006) or RIG-I (Plumet et al., 2007) in the host cell
response to MV. We have found that, for the morbillivirus RPV, the C
protein but not the V protein inhibits the activation of the IFN-β
promoter, and does so whether the inducing agent is dsRNA or a viral
interferon inducer. In addition, abrogationof expressionof theCprotein
(but not the V protein) in recombinant rinderpest viruses led to much
greater induction of expression from the IFN-βpromoter. Such a role for
the morbillivirus C protein ﬁts with previously published observations
on a recombinant MV which does not express C and which showed
increased IFN induction (Nakatsu et al., 2006), and several studies of C
knockout MV or RPV which found that they have reduced growth in
interferon-producing cells (Baron and Barrett, 2000; Devaux and
Cattaneo, 2004; Escofﬁer et al., 1999; Takeuchi et al., 2005), more so
than V knockout equivalent viruses. On the other hand, Childs et al.
(2007) showed that MV V protein inhibited IFN-β promoter activation
in a similar fashion to PIV5 V, and bound tomda-5. In those studies, the
V expression construct used was not modiﬁed to prevent expression
of the C protein from the overlapping reading frame, whereas our V
and P expression constructs are speciﬁcally mutated to prevent C
expression. Our own studies have shown that unmodiﬁed cDNA
clones of the P or V ORF from RPV will always give rise to expression
of C protein. It may be that the suppression of induction of the IFN-β
promoter observed in that work was due to C expression from the MV
V plasmid, or there may be real differences between RPV and MV V
andC proteins.We have also looked for interaction of the RPV V protein
with mda-5 by co-immunoprecipitation, and can show mda-5
coprecipitating with PIV5 V as previously published (Andrejeva et al.,
2004), but not RPV V-mda-5 interaction (data not shown). It may be
that the interaction of morbillivirus V proteins with mda-5 is relatively
weak, being strong enough to be detected in a yeast 2-hybrid system
(Childs et al., 2007) but not strong enough to be shown by
coimmunoprecipitation, or there may be a deﬁnite difference between
MV and RPV, and further work is needed to clarify this discrepancy.
In our hands, both RPV C and PIV5 V proteins suppressed the
activation of the IFN-β promoter by NDV. Induction of IFN by NDV is
thought to occur through RIG-I (Kato et al., 2005), not least because the
NDV V protein binds to and inhibits mda-5 action (Childs et al., 2007),
andwe showed that our NDVpreparation required RIG-I to activate the
IFN-β promoter. It remains to be determined where in the induction
pathway PIV5 V protein is having its effect, thoughwe have noted that
PIV5 V, like RPV C, localises to the nucleus in transfected cells.
The mechanism(s) by which the C protein inhibits activation of the
IFN-β promoter is not clear. Overexpression of components of the
pathway bywhich IRF-3 is activated in response to cytoplasmic dsRNA
show that RPV C acts downstream of all of them. The predominantly
nuclear localisation of the protein, and the fact that IRF-3 appears to
be activated and translocated to the nucleus normally in RPV-infected
cells or after NDV infection of RPV C-expressing cells, also supports the
hypothesis that the C protein may be acting downstream of IRF-3
140 E.L. Boxer et al. / Virology 385 (2009) 134–142activation, as is the case with the Thogoto virus ML protein, which
prevents IRF-3 dimerisation and binding to c-AMP response element
binding protein (CREB) binding protein (CBP) (Jennings et al., 2005).
Further studies are required to map the exact point(s) on the IFN
induction pathway at which RPV acts. It will be interesting to
determine the requirement for nuclear localisation for the RPV C
protein to exert its observed effects on IFN induction. One interesting
point is that, while one potential nuclear localisation signal (NLS)
exists in the RPV C protein sequence, it is not conserved between
morbillivirus C proteins; the NLS identiﬁed in the C protein of MV
(Nishie et al., 2007) is also not found in the C proteins of other
morbilliviruses.
Materials and methods
Cells and viruses
A549 cells were maintained in Dulbecco's Minimal Essential
Medium (DMEM) containing 5%(v/v) foetal calf serum (FCS), penicillin
(100 IU/ml) and streptomycin (10 μg/ml). Vero-SLAM cells (the kind
gift of Dr Rick De Swart, Erasmus Medical College, The Netherlands)
weremaintained in the samemedium,with addition of 0.5 μg/ml G418
every 5th passage. TheHuh-7.5 cell linewas obtained fromProf C. Rice,
Rockefeller University, New York, USA, via the lab of Prof Mark Harris,
University of Leeds, UK, and was maintained in DMEM containing 10%
FCS,1× non-essential amino acids (Invitrogen) and antibiotics as above.
RPV strain Saudi/81 (RPV-Sa) was a non-recombinant virus and was
grown from freeze-dried tissue from an infected animal. All other
viruses were recombinant. Those previously published were:
recombinant Plowright (RBOK) vaccine strain of RPV (RPV-RBOK)
(Baron and Barrett,1997; Das et al., 2000a); RPV RBOKmutants that do
not express the V or C proteins (RPV V-, RPV C-) (Baron and Barrett,
2000); recombinant virulent RPV Kabete ‘O’ (RPV-KO) and P gene
swaps (RBOK-KP, KO-RP) (Baron et al., 2005). Recombinant RBOK
containing the Saudi/81 P gene was prepared by exchanging the
sequence between the unique PacI and SbfI sites in pMDB-RPV2C (Das
et al., 2000a)(end of the N gene and end of the P gene respectively)
with the equivalent sequence from the Saudi/81 strain of RPV, giving
rise to plasmid pRPV-SaP. The RPV-Saudi sequence was prepared by
RT-PCR from RNA isolated from infected cells, incorporating PacI and
SbfI sites in the PCR primers used. Tomake the variant of this virus that
did not express the C protein, overlap PCR mutagenesis was used
during preparation of the P gene PCR amplicon to insert multiple stop
codons at the start of the Cprotein open reading framewithout altering
the P/V open reading frame. The modiﬁed P gene was then used to
replace the P gene in pMDB-RPV2C, giving pRPV-SaPCStop. Virus
rescue was performed in Vero-SLAM cells using fowlpox-T7 as the
source of the T7 RNA polymerase (Das et al., 2000b). The P genes of the
resultant rescued viruses were checked, after passage of the virus, by
RT-PCR of genome 1473 (∼250 bases upstream of the P gene) to 3481
(∼55 bases downstream of the P gene) and sequencing of the resultant
amplicon.
All rinderpest virus preparations used were grown and titred in
Vero-SLAM cells, and were checked regularly for mycoplasma
contamination. The virus titre was determined as the 50% tissue
culture infectious dose (TCID50). All the strains used grew to similar
ﬁnal titres (105.5–106.2) with the exception of C protein knockout
viruses, which grow to lower ﬁnal titres in all cell lines. The Ulster 2C
vaccine strain of Newcastle disease virus (NDV) (grown in eggs) was
the kind gift of Prof W. Barclay, Imperial College, London, UK. The NDV
titre was determined as the TCID50 in Vero cells.
Plasmids
Except where indicated, all DNA manipulation was done following
standard methods. Plasmids were cloned and grown in Escherichia coli(DH5α strain) and puriﬁed on CsCl gradients. The pcDNA construct
containing the RPV-RBOK C protein open reading frame has been
previously described (Nanda and Baron, 2006); constructs encoding
the RPV-Sa P, C and V proteins were similarly prepared by PCR and
PCR-overlap mutagenesis. All three had a V5 epitope tag added at the
5′ end of the coding sequence. Furthermodiﬁcationsweremade to the
P and V expression constructs to include three stop codons into the C
open reading frame just after the C protein start codon, without
altering the P or V protein sequences. Full details of the primers used
for PCR and themodiﬁcations used to prevent expression of C from the
P and V constructs are available from the authors on request. All PCRs
were performed using proofreading polymerase (KOD; Novagen). All
the PCR products introduced into plasmids were sequenced entirely
following the manufacturer's protocols (Beckman Coulter). The
plasmids encoding the PIV5 V protein (pEF-SV5 V) (Didcock et al.,
1999), human RIG-I and human mda-5 were the kind gift of Prof R.E.
Randal, University of St Andrews, UK. The plasmids pJATLac (contains a
beta-galactosidase gene under the control of the rat beta-actin
promoter and was used as a transfection control for all reporter gene
assays) (Masson et al., 1992) and pIFΔ(−116)lucter, a reporter plasmid
with the ﬁreﬂy luciferase gene under the control of the human IFN-β
promoter (King and Goodbourn, 1994) were the kind gift of Prof S.
Goodbourn, St George's Hospital Medical School, London, UK. Plasmids
p55C1Bluc andp55A2luc (Yoneyamaet al.,1996), containing promoters
with multiple copies of, respectively, the IRF-3 and NF-κB binding sites
from the IFN-β promoter, and the plasmid encoding IRF-3were the gift
of Prof T. Fujita, TokyoMetropolitan Institute ofMedical Science, Tokyo,
Japan. The plasmid encoding humanmitochondrial anti-viral signalling
protein (MAVS) was the gift of Prof Z J Chen, UTSW Medical Center,
Dallas, Texas, that encoding TANK-binding kinase 1 (TBK1) was from
Prof J. Hiscott, McGill University, Montreal, Canada and that encoding
I-kappa-B kinase epsilon (IKK-ɛ) was from Dr U. Siebenlist, NIAD,
Bethesda, MD, USA. Plasmid pAP-1-luc was from Stratagene. Poly(I:C)
(Sigma) was used as dsRNA throughout.
Transfections and enzyme assays
All transfections were carried out with TransIT LT1 (Mirus)
according to the manufacturer's instructions. A ratio of 3 μl LT1 per
μg DNA or dsRNAwas used. Cells were plated at 105 per well in 12-well
plates 1 day before use. Six hours after addition of the plasmid
transfection mix, the medium was removed and replaced with fresh
medium. Cells were lysed and luciferase and beta-galactosidase were
measured as previously described (Nanda and Baron, 2006). All
reporter gene assays were carried out in duplicate or (usually)
triplicate wells, and all experiments were carried out at least three
times. The ratio of luciferase to beta-galactosidase for each samplewas
calculated as the number of relative light units (RLUs). The number of
RLUs in each experiment was normalised by setting the average of a
suitable positive control to 100%; this allowedmultiple experiments to
be combined, since the absolute value of the RLUs varied from
experiment to experiment, even though the pattern of stimulation or
suppression of the reporter (RLUs) was the same. Post-hoc analysis of
the multiple conditions in each assay was performed by calculating,
for each set of experiments, Tukey's minimum signiﬁcant difference
(MSD) (Armitage, 1971) at p=0.05; differences greater than this MSD
were considered as signiﬁcant.
SDS-PAGE and Western blots were carried out as previously
described (Nanda and Baron, 2006). Antibodies used were mouse
monoclonal antibody to RPV P ‘2-1’ (Sugiyama et al., 1989) and mouse
monoclonal antibody to the V5 epitope tag (Serotec).
Immunoﬂuorescence
Immunoﬂuorescence studies were carried out as previously
described (SleemanandBaron, 2005). In experimentswithRPV-infected
141E.L. Boxer et al. / Virology 385 (2009) 134–142A549 cells, mouse monoclonal antibody against the beta chain of the
human type 1 IFN receptor (clone MMHAR-2) was included in the
medium at 10 μg/ml to block the receptor (Colamonici and Domanski,
1993). IRF-3 was detected using rabbit anti-IRF-3 from abCam. RPV
infectionwas identiﬁed usingmouse anti-RPV P protein ‘2-1’ (Sugiyama
et al., 1989). The V5 epitope tag attached to the amino terminus of the
RPV-Sa V and C proteins was detected with monoclonal anti-V5 tag
antibody, a gift from Prof R.E. Randal, University of St. Andrews, UK.
Acknowledgments
Wegratefully acknowledge the receipt of useful plasmids, virus and
cells fromProf. R. Randall, St. Andrew's University, Scotland, UK; Prof S.
Goodbourn, St George's Hospital Medical School, London, UK; Dr R. De
Swart, Erasmus Medical College, The Netherlands; Prof W. Barclay,
Imperial College, London, UK; Prof T. Fujita, Tokyo Metropolitan
Institute of Medical Science, Tokyo, Japan; Prof J. Hiscott, McGill
University, Montreal, Canada; Prof C. Rice, Rockefeller University, New
York, USA; Prof M. Harris, University of Leeds, UK; Dr U Siebenlist,
NIAD, NIH, Maryland, USA; Prof Z Chen, UTSW, Texas, USA and Dr. K.
Brzózka, Max-von-Pettenkofer institut, Muenchen, Germany. We
thank Profs Randall and Goodbourn for useful discussions. This work
was supported by a Biotechnology and Biological Sciences Research
Council (BBSRC) studentship to ELB, an IAH studentship to SKN, and
BBSRC project BBSEI00001014 (MDB).
References
Andrejeva, J., Young, D.F., Goodbourn, S., Randall, R.E., 2002. Degradation of STAT1 and
STAT2 by the V proteins of simian virus 5 and human parainﬂuenza virus type 2,
respectively: consequences for virus replication in the presence of alpha/beta and
gamma interferons. J. Virol. 76 (5), 2159–2167.
Andrejeva, J., Childs, K.S., Young, D.F., Carlos, T.S., Stock, N., Goodbourn, S., Randall, R.E.,
2004. TheVproteins of paramyxoviruses bind the IFN-inducible RNAhelicase,mda-5,
and inhibit its activation of the IFN-beta promoter. Proc. Natl. Acad. Sci. U. S. A. 101
(49), 17264–17269.
Armitage, P., 1971. Statistical Methods in Medical Research. Blackwell Scientiﬁc
Publications, Oxford.
Baron, M.D., 2005. Wild-type rinderpest virus uses SLAM (CD150) as its receptor. J. Gen.
Virol. 86 (Pt. 6), 1753–1757.
Baron, M.D., Barrett, T., 1997. Rescue of rinderpest virus from cloned cDNA. J. Virol. 71,
1265–1271.
Baron, M.D., Barrett, T., 2000. Rinderpest viruses lacking the C and V proteins show
speciﬁc defects in growth and transcription of viral RNAs. J. Virol. 74 (6), 2603–2611.
Baron, M.D., Banyard, A.C., Parida, S., Barrett, T., 2005. The Plowright vaccine strain of
rinderpest virus has attenuating mutations in most genes. J. Gen. Virol. 86 (Pt. 4),
1093–1101.
Bellini, W.J., Englund, G., Rozenblatt, S., Arnheiter, H., Richardson, C.D., 1985. Measles
virus P gene codes for two proteins. J. Virol. 53, 908–919.
Berghall, H., Siren, J., Sarkar, D., Julkunen, I., Fisher, P.B., Vainionpaa, R., Matikainen, S.,
2006. The interferon-inducible RNA helicase, mda-5, is involved in measles virus-
induced expression of antiviral cytokines. Microbes. Infect./Institut Pasteur 8 (8),
2138–2144.
Brzozka, K., Finke, S., Conzelmann, K.K., 2005. Identiﬁcation of the rabies virus alpha/
beta interferon antagonist: phosphoprotein P interferes with phosphorylation of
interferon regulatory factor 3. J. Virol. 79 (12), 7673–7681.
Cattaneo, R., Kaelin, K., Baczko, K., Billeter, M.A., 1989. Measles virus editing provides an
additional cysteine-rich protein. Cell 56, 759–764.
Childs, K., Stock, N., Ross, C., Andrejeva, J., Hilton, L., Skinner, M., Randall, R., Goodbourn,
S., 2007. mda-5, but not RIG-I, is a common target for paramyxovirus V proteins.
Virology 359 (1), 190–200.
Colamonici, O.R.,Domanski, P.,1993. Identiﬁcationof anovel subunitof the type I interferon
receptor localized to human chromosome 21. J. Biol. Chem. 268 (15), 10895–10899.
Das, S.C., Baron, M.D., Barrett, T., 2000a. Recovery and characterization of a chimeric
rinderpest virus with the glycoproteins of peste-des-petits-ruminants virus:
homologous F and H proteins are required for virus viability. J. Virol. 74, 9039–9047.
Das, S.C., Baron, M.D., Skinner, M.A., T., B., 2000b. Improved technique for transient
expression and negative strand virus rescue using fowlpox T7 recombinant virus in
mammalian cells. J. Virol. Methods 89, 119–127.
Devaux, P., Cattaneo, R., 2004. Measles virus phosphoprotein gene products:
conformational ﬂexibility of the P/V protein amino-terminal domain and C protein
infectivity factor function. J. Virol. 78 (21), 11632–11640.
Didcock, L., Young, D.F., Goodbourn, S., Randall, R.E., 1999. The V protein of simian virus
5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated
degradation. J. Virol. 73, 9928–9933.
Emeny, J.M., Morgan, M.J., 1979. Regulation of the interferon system: evidence that Vero
cells have a genetic defect in interferon production. J. Gen. Virol. 43 (1), 247–252.Escofﬁer, C., Manié, S., Vincent, S., Muller, C.P., Billeter, M.A., Gerlier, D., 1999.
Nonstructural C protein is required for efﬁcient measles virus replication in
human peripheral blood cells. J. Virol. 73, 1695–1698.
FAO (2003). Rinderpest on the ropes. Agriculture21, the magazine of the Food and
Agriculture Organization (0302).
Garcin, D., Marq, J.B., Strahle, L., le Mercier, P., Kolakofsky, D., 2002. All four Sendai Virus
C proteins bind Stat1, but only the larger forms also induce its mono-ubiquitination
and degradation. Virology 295 (2), 256–265.
Gitlin, L., Barchet, W., Gilﬁllan, S., Cella, M., Beutler, B., Flavell, R.A., Diamond, M.S.,
Colonna, M., 2006. Essential role of mda-5 in type I IFN responses to
polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus.
Proc. Natl. Acad. Sci. U. S. A. 103 (22), 8459–8464.
Goodbourn, S., Didcock, L., 2000. Interferons: cell signalling, immune modulation,
antiviral response and virus countermeasures. J. Gen. Virol 81, 2341–2364.
Gotoh, B., Komatsu, T., Takeuchi, K., Yokoo, J., 2002. Paramyxovirus strategies for evading
the interferon response. Rev. Med. Virol. 12 (6), 337–357.
Gotoh, B., Takeuchi, K., Komatsu, T., Yokoo, J., 2003. The STAT2 activation process is a
crucial target of Sendai virus C protein for the blockade of alpha interferon
signaling. J. Virol. 77 (6), 3360–3370.
He, B., Paterson, R.G., Stock, N., Durbin, J.E., Durbin, R.K., Goodbourn, S., Randall, R.E.,
Lamb, R.A., 2002. Recovery of paramyxovirus simian virus 5 with a V protein lacking
the conserved cysteine-rich domain: the multifunctional V protein blocks both
interferon-beta induction and interferon signaling. Virology 303 (1), 15–32.
Hiscott, J., 2007. Triggering the innate antiviral response through IRF-3 activation. J. Biol.
Chem. 282 (21), 15325–15329.
Hornung, V., Ellegast, J., Kim, S., Brzozka, K., Jung, A., Kato, H., Poeck, H., Akira, S.,
Conzelmann, K.K., Schlee, M., Endres, S., Hartmann, G., 2006. 5′-Triphosphate RNA
is the ligand for RIG-I. Science 314 (5801), 994–997.
Horvath, C.M., 2004. Silencing STATs: lessons from paramyxovirus interferon evasion.
Cytokine Growth Factor Rev. 15, 117–127.
Hussain, S.F., Akhtar, A.S., Rweyemamu, M.M., Kaminjolo, K.S., Mugera, G.M., 1982.
Studies on viral interference induced by rinderpest virus: 3. interferon induction by
attenuated and virulent strains of rinderpest virus in tissue culture. Bull. Anim.
Health Prod. Afr. 30, 1–5.
Janeway Jr., C.A., Medzhitov, R., 2002. Innate immune recognition. Annu. Rev. Immunol.
20, 197–216.
Jennings, S., Martinez-Sobrido, L., Garcia-Sastre, A., Weber, F., Kochs, G., 2005. Thogoto
virus ML protein suppresses IRF3 function. Virology 331 (1), 63–72.
Jordan, I.K., Sutter IV, B.A., McClure, M.A., 2000. Molecular evolution of the
paramyxoviridae and rhabdoviridae multiple-protein-encoding P gene. Mol. Biol.
Evol. 17, 75–86.
Kato, H., Sato, S., Yoneyama, M., Yamamoto, M., Uematsu, S., Matsui, K., Tsujimura, T.,
Takeda, K., Fujita, T., Takeuchi, O., Akira, S., 2005. Cell type-speciﬁc involvement of
RIG-I in antiviral response. Immunity 23, 19–28.
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S.,
Jung, A., Kawai, T., Ishii, K.J., Yamaguchi, O., Otsu, K., Tsujimura, T., Koh, C.S., Reis e
Sousa, C., Matsuura, Y., Fujita, T., Akira, S., 2006. Differential roles of MDA5 and RIG-I
helicases in the recognition of RNA viruses. Nature 441 (7089), 101–105.
King, P., Goodbourn, S., 1994. The beta-interferon promoter responds to priming
through multiple independent regulatory elements. J. Biol. Chem. 269 (48),
30609–30615.
Komatsu, T., Takeuchi, K., Yokoo, J., Gotoh, B., 2002. Sendai virus C protein impairs both
phosphorylation and dephosphorylation processes of Stat1. FEBS Lett. 511 (1–3),
139–144.
Komatsu, T., Takeuchi, K., Yokoo, J., Gotoh, B., 2004. C and V proteins of Sendai virus
target signaling pathways leading to IRF-3 activation for the negative regulation of
interferon-beta production. Virology 325 (1), 137–148.
Kubota, T., Yokosawa, N., Yokota, S., Fujii, N., 2001. C terminal Cys-rich region of mumps
virus structural V protein correlates with block of interferon alpha and gamma
signal transduction pathway through decrease of STAT1-alpha. Biochem. Biophys.
Res. Commun. 283 (1), 255–259.
Maniatis, T., Falvo, J.V., Kim, T.H., Kim, T.K., Lin, C.H., Parekh, B.S., Wathelet, M.G., 1998.
Structure and function of the interferon-beta enhanceosome. Cold Spring Harbor
Symp. Quant. Biol. 63, 609–620.
Masson, N., Ellis, M., Goodbourn, S., Lee, K.A., 1992. Cyclic AMP response element-
binding protein and the catalytic subunit of protein kinase A are present in F9
embryonal carcinoma cells but are unable to activate the somatostatin promoter.
Mol. Cell. Biol. 12 (3), 1096–1106.
Mosca, J.D., Pitha, P.M., 1986. Transcriptional and posttranscriptional regulation of
exogenous human beta interferon gene in simian cells defective in interferon
synthesis. Mol. Cell. Biol. 6 (6), 2279–2283.
Nakatsu, Y., Takeda, M., Ohno, S., Koga, R., Yanagi, Y., 2006. Translational inhibition and
increased interferon induction in cells infected with C protein-deﬁcient measles
virus. J. Virol. 80 (23), 11861–11867.
Nanda, S.K., Baron, M.D., 2006. Rinderpest virus blocks type I and type II interferon
action: role of structural and nonstructural proteins. J. Virol. 80 (15), 7555–7568.
Naniche, D., Yeh, A., Eto, D., Manchester, M., Friedman, R.M., Oldstone, M.B.A., 2000.
Evasion of host defenses by measles virus: wild-type measles virus infection
interferes with the induction of alpha/beta interferon production. J. Virol. 74,
7478–7484.
Nishie, T., Nagata, K., Takeuchi, K., 2007. The C protein of wild-typemeasles virus has the
ability to shuttle between the nucleus and the cytoplasm. Microbes Infect./Institut
Pasteur 9 (3), 344–354.
Nishio, M., Tsurudome, M., Ito, M., Garcin, D., Kolakofsky, D., Ito, Y., 2005. Identiﬁcation
of paramyxovirus V protein residues essential for STAT protein degradation and
promotion of virus replication. J. Virol. 79 (13), 8591–8601.
142 E.L. Boxer et al. / Virology 385 (2009) 134–142Ono, N., Tatsuo, H., Hidaka, Y., Aoki, T., Minagawa, H., Yanagi, Y., 2001. Measles viruses on
throat swabs from measles patients use signaling lymphocytic activation molecule
(CDw150) but not CD46 as a cellular receptor. J. Virol. 75 (9), 4399–4401.
Park, M.S., Garcia-Sastre, A., Cros, J.F., Basler, C.F., Palese, P., 2003. Newcastle disease virus
V protein is a determinant of host range restriction. J. Virol. 77 (17), 9522–9532.
Pichlmair, A., Schulz, O., Tan, C.P.,Naslund, T.I., Liljestrom, P.,Weber, F., Reis e Sousa, C., 2006.
RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates.
Science 314 (5801), 997–1001.
Plumet, S., Herschke, F., Bourhis, J.M., Valentin, H., Longhi, S., Gerlier, D., 2007. Cytosolic
5′-triphosphate ended viral leader transcript of measles virus as activator of the RIG
I-mediated interferon response. PLoS ONE 2, e279.
Poole, E., He, B., Lamb, R.A., Randall, R.E., Goodbourn, S., 2002. The V proteins of simian
virus 5 and other paramyxoviruses inhibit induction of interferon-beta. Virology
303 (1), 33–46.
Rodriguez, J.J., Parisien, J.P., Horvath, C.M., 2002. Nipah virus V protein evades alpha and
gamma interferons by preventing STAT1 and STAT2 activation and nuclear
accumulation. J. Virol. 76 (22), 11476–11483.
Seth, R.B., Sun, L., Ea, C.K., Chen, Z.J., 2005. Identiﬁcation and characterization of MAVS, a
mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell
122 (5), 669–682.
Shaffer, J.A., Bellini, W.J., Rota, P.A., 2003. The C protein of measles virus inhibits the type
I interferon response. Virology 315 (2), 389–397.
Sharma, S., tenOever, B.R., Grandvaux, N., Zhou, G.P., Lin, R., Hiscott, J., 2003. Triggering
the interferon antiviral response through an IKK-related pathway. Science 300
(5622), 1148–1151.
Sleeman, K., Baron, M.D., 2005. The polymerase (L) protein of rinderpest virus interacts
with the host cell protein striatin. Virology 332 (1), 225–234.
Slifka, M.K., Homann, D., Tishon, A., Pagarigan, R., Oldstone, M.B., 2003. Measles virus
infection results in suppression of both innate and adaptive immune responses to
secondary bacterial infection. J. Clin. Invest. 111 (6), 805–810.Sugiyama, M., Minamoto, N., Kinjo, T., Hirayama, N., Sasaki, H., Yoshikawa, Y.,
Yamanouchi, K., 1989. Characterization of monoclonal antibodies against four
structural proteins of rinderpest virus. J. Gen. Virol. 70, 2605–2613.
Sumpter Jr., R., Loo, Y.M., Foy, E., Li, K., Yoneyama, M., Fujita, T., Lemon, S.M., Gale Jr., M.,
2005. Regulating intracellular antiviral defense and permissiveness to hepatitis C
virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 79 (5),
2689–2699.
Takeuchi, K., Takeda, M., Miyajima, N., Ami, Y., Nagata, N., Suzaki, Y., Shahnewaz, J.,
Kadota, S., Nagata, K., 2005. Stringent requirement for the C protein of wild-type
measles virus for growth both in vitro and in macaques. J. Virol. 79 (12),
7838–7844.
Tatsuo, H., Ono, N., Yanagi, Y., 2001. Morbilliviruses use signaling lymphocyte activation
molecules (CD150) as cellular receptors. J. Virol. 75 (13), 5842–5850.
Ulane, C.M., Kentsis, A., Cruz, C.D., Parisien, J.P., Schneider, K.L., Horvath, C.M., 2005.
Composition and assembly of STAT-targeting ubiquitin ligase complexes: para-
myxovirus V protein carboxyl terminus is an oligomerization domain. J. virol. 79
(16), 10180–10189.
Vidy, A., Chelbi-Alix, M., Blondel, D., 2005. Rabies virus P protein interacts with STAT1
and inhibits interferon signal transduction pathways. J. Virol. 79 (22), 14411–14420.
Weber, F., Wagner, V., Rasmussen, S.B., Hartmann, R., Paludan, S.R., 2006. Double-
stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not
in detectable amounts by negative-strand RNA viruses. J. Virol. 80 (10),
5059–5064.
Yokota, S., Saito, H., Kubota, T., Yokosawa, N., Amano, K., Fujii, N., 2003. Measles virus
suppresses interferon-alpha signaling pathway: suppression of Jak1phosphorylation
and association of viral accessory proteins, C and V, with interferon-alpha receptor
complex. Virology 306 (1), 135–146.
Yoneyama, M., Suhara, W., Fukuhara, Y., Sato, M., Ozato, K., Fujita, T., 1996. Autocrine
ampliﬁcation of type I interferon gene expression mediated by interferon
stimulated gene factor 3 (ISGF3). J. Biochem. (Tokyo) 120 (1), 160–169.
